NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics projected cash runway "into 2027" tied to clinical milestones that never materialized -- then cut 35% of its workforce the same day both pivotal trials failed.

NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

During the Q2 2025 earnings call on August 6, 2025, CFO Michael Milligan told investors: "We anticipate our cash runway to support operations into 2027 well beyond all of our upcoming clinical milestones." That projection was anchored to navacaprant milestones -- KOASTAL-3 data expected in Q1 2026 and KOASTAL-2 data expected in Q2 2026. On the Q1 2025 call, President Josh Pinto provided definitive timing for both readouts without referencing the atypical patient-mix risks observed in the already-failed KOASTAL-1 trial.

Today's simultaneous trial failure and 35% headcount reduction indicate the runway projection had become materially dependent on outcomes the company did not achieve.

Shareholders who suffered losses on their Neumora Therapeutics investment may click here to get more information about the investigation. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

Levi & Korsinsky, LLP | Top 50 Securities Firm | [phone] | www.zlk.com

Frequently Asked Questions About the NMRA Investigation

Q: How much did NMRA stock drop? A: Neumora Therapeutics shares collapsed on June 15, 2026 after the company disclosed that navacaprant failed both remaining Phase 3 depression trials and announced an immediate approximately 35% workforce reduction. Investors who purchased shares at higher prices may be eligible to participate in the investigation.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Neumora Therapeutics made materially false or misleading statements regarding navacaprant's Phase 3 prospects, cash runway projections tied to clinical milestones, and financial disclosures.

Q: What do NMRA investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone]. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my NMRA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NMRA and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.